Dividend Report: Bristol-Myers Squibb Company (NYSE:BMY) expected to pay $0.38 on Nov 1, 2016

Dividend Report: Bristol Myers Squibb Company (NYSE:BMY) expected to pay $0.38 on Nov 1, 2016

Bristol-Myers Squibb Company (NYSE:BMY) is expected to pay $0.38 on Nov 1, 2016. The indicated annual dividend is $1.52. Shareholders owning the stock before Oct 5, 2016 will be eligible to receive the payout. Based on Bristol-Myers Squibb Company’s current price of $54.66, the dividend is 0.70%. This dividend’s record date is Oct 7, 2016 and the announcement date is Aug 4, 2016. The stock increased 1.37% or $0.74 during the last trading session, hitting $54.66. Bristol-Myers Squibb Co (NYSE:BMY) has declined 14.89% since March 1, 2016 and is downtrending. It has underperformed by 24.13% the S&P500.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company has a market cap of $91.41 billion. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. It has a 31.99 P/E ratio. Small molecule drugs are administered orally in the form of a pill or tablet.

Insitutional Activity: The institutional sentiment increased to 0.94 in 2016 Q2. Its up 0.01, from 0.93 in 2016Q1. The ratio increased, as 47 funds sold all Bristol-Myers Squibb Co shares owned while 542 reduced positions. 84 funds bought stakes while 472 increased positions. They now own 1.19 billion shares or 3.56% less from 1.23 billion shares in 2016Q1.
British Columbia Inv Mngmt holds 0.66% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 1.03M shares. The Illinois-based Balyasny Asset Management Lc has invested 0.05% in Bristol-Myers Squibb Co (NYSE:BMY). Liberty Capital Mgmt Inc last reported 0.3% of its portfolio in the stock. The Texas-based Cullen Frost Bankers has invested 1.01% in Bristol-Myers Squibb Co (NYSE:BMY). De Burlo Gru holds 2.7% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 151,687 shares. Ronald Blue And Lc holds 0.03% or 10,228 shares in its portfolio. Woodstock has invested 0.43% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Outfitter Advsr Ltd has 0.24% invested in the company for 7,722 shares. Hightower Advsrs Ltd Company has 0.9% invested in the company for 964,579 shares. The Pennsylvania-based Pnc Fincl Gp has invested 0.59% in Bristol-Myers Squibb Co (NYSE:BMY). The Tennessee-based Woodmont Inv Counsel Ltd Liability Com has invested 0.15% in Bristol-Myers Squibb Co (NYSE:BMY). Peak Asset Lc, a Colorado-based fund reported 8,631 shares. Davidson & Garrard Inc accumulated 0.84% or 46,431 shares. Bartlett & Co Ltd Limited Liability Company holds 443,982 shares or 1.61% of its portfolio. Mutual Of America Mgmt Ltd Liability holds 0.3% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 194,081 shares.

Insider Transactions: Since May 3, 2016, the stock had 0 insider purchases, and 9 insider sales for $16.83 million net activity. Another trade for 23,200 shares valued at $1.73 million was made by ANDREOTTI LAMBERTO on Thursday, July 7. Caforio Giovanni also sold $2.47 million worth of Bristol-Myers Squibb Co (NYSE:BMY) shares. Shares for $255,004 were sold by Caldarella Joseph C. Bancroft Charles A sold $2.14 million worth of stock or 30,201 shares. LEUNG SANDRA sold $5.11M worth of stock or 72,544 shares. The insider Elicker John E sold 11,820 shares worth $859,219.

Bristol-Myers Squibb Co (NYSE:BMY) Ratings Coverage

Out of 15 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 5 rate it a “Buy”, 3 “Sell”, while 7 “Hold”. This means 33% are positive. Bristol-Myers Squibb Company has been the topic of 33 analyst reports since July 28, 2015 according to StockzIntelligence Inc. On Tuesday, March 15 the stock rating was maintained by Jefferies with “Hold”. The company was downgraded on Monday, January 25 by BMO Capital Markets. As per Monday, May 23, the company rating was initiated by Hilliard Lyons. Jefferies maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Thursday, August 27. Jefferies has “Hold” rating and $59 price target. Barclays Capital maintained the shares of BMY in a report on Tuesday, December 1 with “Equal Weight” rating. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Buy” rating by Guggenheim on Wednesday, December 2. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Equal-Weight” rating by Barclays Capital on Friday, September 9. Piper Jaffray upgraded the shares of BMY in a report on Monday, August 24 to “Underweight” rating. The stock has “Buy” rating given by UBS on Friday, April 29. Citigroup maintained the shares of BMY in a report on Tuesday, September 20 with “Buy” rating.

More recent Bristol-Myers Squibb Co (NYSE:BMY) news were published by: Forbes.com which released: “Ex-Dividend Reminder: American Eagle Outfitters, WGL Holdings and Bristol …” on October 03, 2016. Also Fool.com published the news titled: “This Crushing Blow Sent Bristol-Myers Squibb Co. Down 23% in August” on September 08, 2016. Seekingalpha.com‘s news article titled: “Bristol-Myers Squibb Has Reached Bottom” with publication date: September 13, 2016 was also an interesting one.

BMY Company Profile

Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: ,

Related posts

Leave a Comment